Pharmacovigilance and Drug Safety Software Market Size 2031

Pharmacovigilance and Drug Safety Software Market Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Offering (Software and Services), Deployment (Cloud and On-Premises), Enterprise Size (Large Enterprises and SMEs), Form (Standard and Customized), Functionality (Signal and Risk Management, Issue Tracking and Adverse Event Tracking, Case Management, Clinical Safety Management and Clinical Trial Safety, Quality and Compliance, Medical Writing, Audit Support and Training Compliance, Healthcare Analytics, and Others), End User [Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Business Process Outsourcing (BPO) Firms, and Others], and Geography

Publication Month : Oct 2024

  • Report Code : TIPHC00002557
  • Category : Healthcare IT
  • Status : Published
  • No. of Pages : 388
Inquire Before Buy

PRICING

$5190

$4152

The pharmacovigilance and drug safety software market size is expected to reach US$ 359.30 million by 2031 from US$ 214.39 million in 2023. The market is estimated to record a CAGR of 6.7% during 2023–2031. Cloud-based pharmacovigilance and drug safety software is likely to bring new key trends into the market in the coming years.

Pharmacovigilance and Drug Safety Software Market Analysis

The rising integration of technologies such as artificial intelligence and machine learning with pharmacovigilance and drug safety software to automate drug safety tasks is driving the market. Several key players are integrating these advanced technologies to automate the workflow in the pharmaceutical industry. For instance, in January 2024, PubHive Ltd., a provider of AI-powered scientific safety and literature information workflows, launched centralized Summary of Product Characteristics (SmPC) management software with AI-powered pharmacovigilance workflows for life science companies. The company offers its software to Clinical Research Organizations (CROs) and their pharmacovigilance and drug safety departments. This AI-based solution simplifies and streamlines processes and helps meet compliances, as well as empowers pharmacovigilance teams to work faster and more effectively.

Pharmacovigilance and Drug Safety Software Market Overview

Pharmacovigilance and drug safety software is a vital tool that addresses manual data entry errors and manages the huge volume of safety data, among various other challenges. From clinical trials to post-marketing surveillance, this software is indispensable throughout the drug development lifecycle. Pharmacovigilance and drug safety software helps reduce adverse event processing time and improve patient safety through early signal detection. As regulations evolve and collaboration between European companies intensifies, the adoption of pharmacovigilance and drug safety software will become imperative for pharmaceutical companies and regulatory bodies. In 2022, the Pharmaceutical Inspection Co-operation Scheme (PIC/S) updated its guidelines on pharmacovigilance to adhere to international standards, highlighting the importance of robust pharmacovigilance and drug safety software. Also, in March 2024, The US Food and Drug Administration (FDA) provided guidance specifying the submission of investigational new drug (IND) safety reports for severe and suspected adverse events related to pharma drugs. These reports are submitted in electronic common technical document (eCTD) formats using PDF files. Further, the software ensures compliance with regulatory standards by facilitating the creation of comprehensive safety reports and submissions to regulatory authorities, which helps companies avoid penalties and maintain their reputation.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Pharmacovigilance and Drug Safety Software Market: Strategic Insights

pharmacovigilance-pv-and-drug-safety-software-market
Market Size Value inUS$ 160.67 Million in 2019
Market Size Value byUS$ 292.97 Million by 2027
Growth rateCAGR of 7.6% from 2020-2027
Forecast Period2020-2027
Base Year2020
Analyst Image

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Pharmacovigilance and Drug Safety Software Market Drivers and Opportunities

Rise in Incidences of Adverse Drug Reactions to Favor Market

The cases of adverse drug reactions (ADRs) are increasing worldwide owing to the increasing prevalence of chronic diseases. As all drugs have the potential for adverse drug reactions, a risk-benefit analysis is necessary whenever a drug is prescribed. ADRs remain a challenge in modern healthcare, particularly given the growing complexity of therapeutics, an aging population, and rising multimorbidity across the globe. Pharmacovigilance software enables healthcare providers and pharmaceutical companies to collect, analyze systematically, and report data related to ADRs and overcome the challenges associated with it. The increasing prevalence of ADRs across the globe is propelling the demand for pharmacovigilance and drug safety software. According to the database of ADRs available in the US Food and Drug Administration's Adverse Event Reporting System (FAERS), in 2022, more than 1.25 million severe adverse cases were reported, along with over 175,000 deaths.

ADRs are a major cause of the growing mortality death rate across the globe. According to the report of The European Union Drugs Agency (EUDA), in terms of overdoses, the mortality rate in the European Union in 2021 accounted for ~18.3 deaths per million people aged from 15 to 64. Also, at least 6,166 deaths caused by overdoses involving illicit drugs occurred in the European Union in 2021 (5,796 in 2020). This total reached ~6,677 deaths when Norway and Türkiye were included (6,434 in 2020).

Theophylline and respiratory depression exposure grows with the use of macrolide antibiotics and increased consumption of vitamin K, leading to ADRs. As more ADRs are reported and recognized, pharmaceutical companies, healthcare providers, and regulatory bodies face greater pressure to improve drug safety monitoring and reporting processes. Pharmacovigilance and drug safety software helps avoid the risks associated with excessive drug consumption. This software helps streamline the process of detecting, assessing, and preventing adverse effects, enabling faster response times and more accurate risk assessments. Thus, the rising incidences of adverse drug reactions fuel the global pharmacovigilance and drug safety software market growth.

Globalization of Pharmacovigilance

Pharmacovigilance is the process of monitoring and evaluating adverse drug reactions, and it is a major component of effective drug regulation systems, clinical practice, and public health programs. The globalization of pharmacovigilance fosters collaboration among stakeholders, including regulatory authorities, healthcare providers, and pharmaceutical companies. For instance, the European Medicines Agency (EMA) has placed a growing importance on collaborating with international pharmaceutical regulators to focus on areas such as the safety of medicines, inspections, and exchange of information on issues of mutual concern. Such a collaborative environment enhances data sharing and improves the overall understanding of drug safety profiles. As companies seek to leverage these global networks, the need for integrated pharmacovigilance solutions that can operate across the globe is becoming increasingly essential.

Governments of various countries across the globe are conducting pharmacovigilance programs by collaborating with regulatory bodies in their respective countries. Regulators understand the importance of pharmacovigilance in ensuring drug safety. For instance, in North America, the US FDA regulates guidelines, laws, and regulations to conduct several practices such as the Good Clinical Practice Program (GCP) and Good Pharmacovigilance Practice Program (GVP) applicable to biomedical products. Further, in September 2024, the Indian Pharmacopoeia Commission and Central Drugs Standard Control Organization published version 2.0 of their pharmacovigilance guidelines by enacting changes such as the extension of the deadline for reporting non-serious adverse ADRs events and revising the record-keeping requirements. Further, Malaysia's National Pharmaceutical Regulatory Agency published the second revised edition of its guidelines on bioequivalence and pharmacovigilance inspections. The agency provided more information on the drug inspection process and the scope of assessments related to drug evaluations. The Philippine Food and Drug Administration (FDA) has also published detailed actions in response to feedback on the registration of new drug products and to provide information on active pharmaceutical ingredients (APIs) for human usage.

Pharmacovigilance and Drug Safety Software Market Report Segmentation Analysis

Key segments that contributed to the derivation of the pharmacovigilance and drug safety software market analysis are offerings, organization size, deployment, form, functionality, and end user.

  • Based on organization size, the Europe pharmacovigilance and drug safety software market is bifurcated into large enterprises and SMEs. The large enterprises segment dominated the market in 2023.
  • In terms of offerings, the market is divided into software and services. The software segment held a larger share of the market in 2023.
  • Based on deployment, the Europe pharmacovigilance and drug safety software market is bifurcated into cloud and on-premises. The cloud segment dominated the market in 2023
  • Based on form, the Europe pharmacovigilance and drug safety software market is divided into standard and customized. The standard segment dominated the market in 2023.
  • By functionality, the Europe pharmacovigilance and drug safety software market is segmented into case management, signal and risk management, quality and compliance, audit support and training compliance, issue tracking and adverse event tracking, clinical safety management and clinical trial safety, medical writing, healthcare analytics, and others. The signal and risk management segment held the largest share of the market in 2023.
  • Based on end user, the Europe pharmacovigilance and drug safety software market is segmented into pharmaceutical and biotechnology companies, contract research organizations, business process outsourcing firms, and other pharmacovigilance service providers. The pharmaceutical and biotechnology companies segment dominated the market in 2023.

Pharmacovigilance and Drug Safety Software Market Share Analysis by Geography

The pharmacovigilance and drug safety software market is segmented into five major regions: North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. North America dominated the market in 2023, followed by Europe and APAC.

North America is witnessing tremendous growth in the pharmacovigilance and drug safety software market, owing to the presence of various market players such as IQVIA Oracle Corporation, who are continuously working on the advancement of pharmacovigilance and drug safety software. In July 2024, Oracle Corporation launched an AI-based Oracle Argus platform as a Safety One Intake solution. This solution helps life science organizations to meet growing regulatory requirements as well as mitigate the rising volume of adverse event cases. This new pharmacovigilance platform aimed to increase productivity, improve data privacy, and enhance reporting. Thus, such product innovations by the market players in the region are fueling the growth of the pharmacovigilance and drug safety software market.

Pharmacovigilance and Drug Safety Software Market Report Scope

Pharmacovigilance and Drug Safety Software Market News and Recent Developments

The pharmacovigilance and drug safety software market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the pharmacovigilance and drug safety software market are listed below:

  • ArisGlobal, a market leader in global drug development technology solutions, announced that Medac, a German-based pharmaceutical manufacturer specializing in the fields of oncology and hematology, urology, and autoimmune diseases, chose LifeSphere Safety to modernize its drug safety processes. Precise, patient- and population-specific analysis is crucial for minimizing treatment risks for patients, which supports the best possible treatment outcome. (Source: ArisGlobal, Press Release, May 2023)
  • IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced a strategic collaboration with Argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions. (Source: IQVIA, Press Release, January 2023)

Pharmacovigilance and Drug Safety Software Market Report Coverage and Deliverables

The "Pharmacovigilance and Drug Safety Software Market Size and Forecast (2021–2031)" provides a detailed analysis of the market covering the areas mentioned below:

  • Pharmacovigilance and drug safety software market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Pharmacovigilance and drug safety software market trends as well as market dynamics such as drivers, restraints, and key opportunities
  • Detailed PEST and SWOT analysis
  • Pharmacovigilance and drug safety software market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmacovigilance and drug safety software market
  • Detailed company profiles
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Software Type ; Delivery Mode ; and End User , and Geography

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What are the future trends of the pharmacovigilance and drug safety software market?

Integration of cloud-based platforms that offers real-time access to data from anywhere across the globe, enabling pharmaceutical companies to respond swiftly to emerging safety concerns.

Which are the leading players operating in the pharmacovigilance and drug safety software market?

ArisEurope, ICON plc, Syneos Health, Accenture, IQVIA, Genpact, Cognizant, Paraxel International Corporation, Laboratory Corporation of America Holdings, Max Application, Clinevo Technologies, Qinecsa Solutions, AB Cube, and Veeva Systems are among the key players operating in the global pharmacovigilance and drug safety software market.

What is the estimated global market size for the pharmacovigilance and drug safety software market in 2023?

The pharmacovigilance and drug safety software market was valued at US$ 214.39 billion in 2023 and is anticipated to grow at a CAGR of 6.7% over the forecast period.

What are the driving factors impacting the pharmacovigilance and drug safety software market?

The rising cases of adverse drug reactions (ADRs) worldwide owing to the increasing prevalence of chronic diseases drives the market growth.

Which is the fastest-growing region in the pharmacovigilance and drug safety software market?

Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Which is the leading offering segment in the pharmacovigilance and drug safety software market?

The software segment led the pharmacovigilance and drug safety software market with a significant share in 2023.

What will the pharmacovigilance and drug safety software market size be by 2031?

The pharmacovigilance and drug safety software market are expected to reach US$ 359.30 million by 2031 and is expected to register a CAGR of 6.7% during 2023–2031.

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:

3.2.2 Macro-economic factor analysis:

3.2.3 Developing base number:

3.2.4 Data Triangulation:

3.2.5 Country level data:

4. Pharmacovigilance and Drug Safety Software Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Ecosystem Analysis

4.3.1 Software/Service Providers:

4.3.2 System Integrators:

4.3.3 Regulatory Bodies:

4.3.4 End-Users:

4.3.5 List of Vendors in the Value Chain

5. Pharmacovigilance and Drug Safety Software Market – Key Market Dynamics

5.1 Pharmacovigilance and Drug Safety Software Market – Key Market Dynamics

5.2 Market Drivers

5.2.1 Rise in Incidences of Adverse Drug Reactions

5.2.2 Globalization of Pharmacovigilance

5.2.3 Surge in Drug Development Spending

5.3 Market Restraints

5.3.1 High Installation and Maintenance Costs

5.4 Market Opportunities

5.4.1 Integration of Software with AI, ML, and NLP

5.5 Future Trends

5.5.1 Cloud-Based Pharmacovigilance and Drug Safety Software:

5.6 Impact of Drivers and Restraints:

6. Pharmacovigilance and Drug Safety Software Market – Global Market Analysis

6.1 Pharmacovigilance and Drug Safety Software Market Revenue (US$ Million), 2021–2031

6.2 Pharmacovigilance and Drug Safety Software Market Forecast Analysis

7. Pharmacovigilance and Drug Safety Software Market Analysis – by Offering

7.1 Software

7.1.1 Overview

7.1.2 Software: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Services

7.2.1 Overview

7.2.2 Services: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

8. Pharmacovigilance and Drug Safety Software Market Analysis – by Deployment

8.1 Cloud

8.1.1 Overview

8.1.2 Cloud: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

8.2 On Premises

8.2.1 Overview

8.2.2 On Premises: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

9. Pharmacovigilance and Drug Safety Software Market Analysis – by Enterprise Size

9.1 Large Enterprises

9.1.1 Overview

9.1.2 Large Enterprises: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

9.2 SMEs

9.2.1 Overview

9.2.2 SMEs: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

10. Pharmacovigilance and Drug Safety Software Market Analysis – by Form

10.1 Standard

10.1.1 Overview

10.1.2 Standard: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

10.2 Customized

10.2.1 Overview

10.2.2 Customized: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11. Pharmacovigilance and Drug Safety Software Market Analysis – by Functionality

11.1 Signal and Risk Management

11.1.1 Overview

11.1.2 Signal and Risk Management: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.2 Issue Tracking and Adverse Event Tracking

11.2.1 Overview

11.2.2 Issue Tracking and Adverse Event Tracking: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.3 Case Management

11.3.1 Overview

11.3.2 Case Management: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.4 Clinical Safety Management and Clinical Trial Safety

11.4.1 Overview

11.4.2 Clinical Safety Management and Clinical Trial Safety: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.5 Quality and Compliance

11.5.1 Overview

11.5.2 Quality and Compliance: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.6 Medical Writing

11.6.1 Overview

11.6.2 Medical Writing: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.7 Audit Support and Training Compliance

11.7.1 Overview

11.7.2 Audit Support and Training Compliance: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.8 Healthcare Analytics

11.8.1 Overview

11.8.2 Healthcare Analytics: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

11.9 Others

11.9.1 Overview

11.9.2 Others: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

12. Pharmacovigilance and Drug Safety Software Market Analysis – by End User

12.1 Pharmaceutical and Biotechnology Companies

12.1.1 Overview

12.1.2 Pharmaceutical and Biotechnology Companies: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

12.2 Contract Research Organizations

12.2.1 Overview

12.2.2 Contract Research Organizations: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

12.3 Business Process Outsourcing (BPO) Firms

12.3.1 Overview

12.3.2 Business Process Outsourcing (BPO) Firms: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

12.4 Others

12.4.1 Overview

12.4.2 Others: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13. Pharmacovigilance and Drug Safety Software Market – Geographical Analysis

13.1 Overview

13.2 North America

13.2.1 North America Pharmacovigilance and Drug Safety Software Market Overview

13.2.2 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.2.3 North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.2.3.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Offering

13.2.4 North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.2.4.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Deployment

13.2.5 North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.2.5.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Enterprise Size

13.2.6 North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.2.6.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Form

13.2.7 North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.2.7.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Functionality

13.2.8 North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.2.8.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by End User

13.2.9 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.2.9.1 North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.2.9.2 United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.2.9.2.1 United States: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.2.9.2.2 United States: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.2.9.2.3 United States: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.2.9.2.4 United States: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.2.9.2.5 United States: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.2.9.2.6 United States: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.2.9.3 Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.2.9.3.1 Canada: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.2.9.3.2 Canada: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.2.9.3.3 Canada: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.2.9.3.4 Canada: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.2.9.3.5 Canada: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.2.9.3.6 Canada: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.2.9.4 Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.2.9.4.1 Mexico: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.2.9.4.2 Mexico: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.2.9.4.3 Mexico: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.2.9.4.4 Mexico: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.2.9.4.5 Mexico: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.2.9.4.6 Mexico: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3 Europe

13.3.1 Europe Pharmacovigilance and Drug Safety Software Market Overview

13.3.2 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.3 Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.3.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Offering

13.3.4 Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.4.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Deployment

13.3.5 Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.5.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Enterprise Size

13.3.6 Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.6.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Form

13.3.7 Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.7.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Functionality

13.3.8 Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3.8.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by End User

13.3.9 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.3.9.1 Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.3.9.2 Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.9.2.1 Germany: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.9.2.2 Germany: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.9.2.3 Germany: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.9.2.4 Germany: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.9.2.5 Germany: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.9.2.6 Germany: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3.9.3 France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.9.3.1 France: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.9.3.2 France: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.9.3.3 France: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.9.3.4 France: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.9.3.5 France: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.9.3.6 France: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3.9.4 United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.9.4.1 United Kingdom: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.9.4.2 United Kingdom: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.9.4.3 United Kingdom: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.9.4.4 United Kingdom: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.9.4.5 United Kingdom: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.9.4.6 United Kingdom: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3.9.5 Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.9.5.1 Italy: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.9.5.2 Italy: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.9.5.3 Italy: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.9.5.4 Italy: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.9.5.5 Italy: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.9.5.6 Italy: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3.9.6 Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.9.6.1 Spain: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.9.6.2 Spain: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.9.6.3 Spain: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.9.6.4 Spain: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.9.6.5 Spain: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.9.6.6 Spain: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.3.9.7 Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.3.9.7.1 Russia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.3.9.7.2 Russia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.3.9.7.3 Russia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.3.9.7.4 Russia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.3.9.7.5 Russia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.3.9.7.6 Russia: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4 Asia Pacific

13.4.1 Asia Pacific Pharmacovigilance and Drug Safety Software Market Overview

13.4.2 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.3 Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.3.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Offering

13.4.4 Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.4.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Deployment

13.4.5 Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.5.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Enterprise Size

13.4.6 Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.6.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Form

13.4.7 Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.7.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Functionality

13.4.8 Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4.8.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by End User

13.4.9 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.4.9.1 Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.4.9.2 China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.9.2.1 China: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.9.2.2 China: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.9.2.3 China: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.9.2.4 China: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.9.2.5 China: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.9.2.6 China: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4.9.3 Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.9.3.1 Japan: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.9.3.2 Japan: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.9.3.3 Japan: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.9.3.4 Japan: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.9.3.5 Japan: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.9.3.6 Japan: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4.9.4 India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.9.4.1 India: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.9.4.2 India: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.9.4.3 India: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.9.4.4 India: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.9.4.5 India: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.9.4.6 India: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4.9.5 South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.9.5.1 South Korea: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.9.5.2 South Korea: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.9.5.3 South Korea: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.9.5.4 South Korea: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.9.5.5 South Korea: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.9.5.6 South Korea: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4.9.6 Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.9.6.1 Australia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.9.6.2 Australia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.9.6.3 Australia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.9.6.4 Australia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.9.6.5 Australia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.9.6.6 Australia: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.4.9.7 Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.4.9.7.1 Rest of APAC: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.4.9.7.2 Rest of APAC: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.4.9.7.3 Rest of APAC: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.4.9.7.4 Rest of APAC: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.4.9.7.5 Rest of APAC: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.4.9.7.6 Rest of APAC: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.5 Middle East and Africa

13.5.1 Middle East and Africa Pharmacovigilance and Drug Safety Software Market Overview

13.5.2 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.5.3 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.5.3.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Offering

13.5.4 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.5.4.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Deployment

13.5.5 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.5.5.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Enterprise Size

13.5.6 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.5.6.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Form

13.5.7 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.5.7.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Functionality

13.5.8 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.5.8.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by End User

13.5.9 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.5.9.1 Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.5.9.2 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.5.9.2.1 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.5.9.2.2 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.5.9.2.3 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.5.9.2.4 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.5.9.2.5 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.5.9.2.6 Saudi Arabia: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.5.9.3 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.5.9.3.1 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.5.9.3.2 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.5.9.3.3 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.5.9.3.4 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.5.9.3.5 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.5.9.3.6 United Arab Emirates: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.5.9.4 South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.5.9.4.1 South Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.5.9.4.2 South Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.5.9.4.3 South Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.5.9.4.4 South Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.5.9.4.5 South Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.5.9.4.6 South Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.5.9.5 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.5.9.5.1 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.5.9.5.2 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.5.9.5.3 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.5.9.5.4 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.5.9.5.5 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.5.9.5.6 Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.6 South and Central America

13.6.1 South and Central America Pharmacovigilance and Drug Safety Software Market Overview

13.6.2 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.6.3 South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.6.3.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Offering

13.6.4 South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.6.4.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Deployment

13.6.5 South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.6.5.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Enterprise Size

13.6.6 South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.6.6.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Form

13.6.7 South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.6.7.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Functionality

13.6.8 South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.6.8.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by End User

13.6.9 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.6.9.1 South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast Analysis – by Country

13.6.9.2 Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.6.9.2.1 Brazil: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.6.9.2.2 Brazil: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.6.9.2.3 Brazil: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.6.9.2.4 Brazil: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.6.9.2.5 Brazil: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.6.9.2.6 Brazil: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.6.9.3 Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.6.9.3.1 Argentina: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.6.9.3.2 Argentina: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.6.9.3.3 Argentina: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.6.9.3.4 Argentina: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.6.9.3.5 Argentina: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.6.9.3.6 Argentina: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

13.6.9.4 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

13.6.9.4.1 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering

13.6.9.4.2 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment

13.6.9.4.3 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size

13.6.9.4.4 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form

13.6.9.4.5 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality

13.6.9.4.6 Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User

14. Competitive Landscape

14.1 Heat Map Analysis by Key Players

14.2 Company Positioning & Concentration

15. Industry Landscape

15.1 Overview

15.2 Market Initiative

15.3 Merger and Acquisition

16. Company Profiles

16.1 ArisGlobal LLC

16.1.1 Key Facts

16.1.2 Business Description

16.1.3 Products and Services

16.1.4 Financial Overview

16.1.5 SWOT Analysis

16.1.6 Key Developments

16.2 Max Application

16.2.1 Key Facts

16.2.2 Business Description

16.2.3 Products and Services

16.2.4 Financial Overview

16.2.5 SWOT Analysis

16.2.6 Key Developments

16.3 Oracle Corp

16.3.1 Key Facts

16.3.2 Business Description

16.3.3 Products and Services

16.3.4 Financial Overview

16.3.5 SWOT Analysis

16.3.6 Key Developments

16.4 Veeva Systems Inc

16.4.1 Key Facts

16.4.2 Business Description

16.4.3 Products and Services

16.4.4 Financial Overview

16.4.5 SWOT Analysis

16.4.6 Key Developments

16.5 IQVIA Holdings Inc

16.5.1 Key Facts

16.5.2 Business Description

16.5.3 Products and Services

16.5.4 Financial Overview

16.5.5 SWOT Analysis

16.5.6 Key Developments

16.6 ICON Plc

16.6.1 Key Facts

16.6.2 Business Description

16.6.3 Products and Services

16.6.4 Financial Overview

16.6.5 SWOT Analysis

16.6.6 Key Developments

16.7 Cognizant Technology Solutions Corp

16.7.1 Key Facts

16.7.2 Business Description

16.7.3 Products and Services

16.7.4 Financial Overview

16.7.5 SWOT Analysis

16.7.6 Key Developments

16.8 Accenture Plc

16.8.1 Key Facts

16.8.2 Business Description

16.8.3 Products and Services

16.8.4 Financial Overview

16.8.5 SWOT Analysis

16.8.6 Key Developments

16.9 Syneos Health Inc

16.9.1 Key Facts

16.9.2 Business Description

16.9.3 Products and Services

16.9.4 Financial Overview

16.9.5 SWOT Analysis

16.9.6 Key Developments

16.10 Genpact Ltd.

16.10.1 Key Facts

16.10.2 Business Description

16.10.3 Products and Services

16.10.4 Financial Overview

16.10.5 SWOT Analysis

16.10.6 Key Developments

16.11 AB Cube S.A.S.

16.11.1 Key Facts

16.11.2 Business Description

16.11.3 Products and Services

16.11.4 Financial Overview

16.11.5 SWOT Analysis

16.11.6 Key Developments

16.12 Laboratory Corp of America Holdings

16.12.1 Key Facts

16.12.2 Business Description

16.12.3 Products and Services

16.12.4 Financial Overview

16.12.5 SWOT Analysis

16.12.6 Key Developments

16.13 Parexel International Corp

16.13.1 Key Facts

16.13.2 Business Description

16.13.3 Products and Services

16.13.4 Financial Overview

16.13.5 SWOT Analysis

16.13.6 Key Developments

16.14 Qinecsa Solutions

16.14.1 Key Facts

16.14.2 Business Description

16.14.3 Products and Services

16.14.4 Financial Overview

16.14.5 SWOT Analysis

16.14.6 Key Developments

16.15 Clinevo Technologies

16.15.1 Key Facts

16.15.2 Business Description

16.15.3 Products and Services

16.15.4 Financial Overview

16.15.5 SWOT Analysis

16.15.6 Key Developments

17. Appendix

17.1 Word Index

17.2 About the Insight Partners

List of Tables

Table 1. Pharmacovigilance and Drug Safety Software Market Segmentation

Table 2. List of Vendors

Table 3. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Table 4. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million) – by Offering

Table 5. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million) – by Deployment

Table 6. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million) – by Enterprise Size

Table 7. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million) – by Form

Table 8. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million) – by Functionality

Table 9. Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million) – by End User

Table 10. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 11. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 12. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 13. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 14. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 15. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 16. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Country

Table 17. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 18. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 19. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 20. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 21. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 22. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 23. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 24. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 25. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 26. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 27. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 28. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 29. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 30. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 31. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 32. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 33. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 34. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 35. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 36. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 37. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 38. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 39. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 40. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 41. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Country

Table 42. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 43. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 44. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 45. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 46. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 47. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 48. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 49. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 50. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 51. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 52. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 53. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 54. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 55. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 56. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 57. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 58. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 59. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 60. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 61. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 62. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 63. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 64. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 65. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 66. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 67. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 68. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 69. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 70. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 71. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 72. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 73. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 74. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 75. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 76. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 77. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 78. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 79. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 80. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 81. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 82. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 83. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 84. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Country

Table 85. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 86. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 87. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 88. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 89. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 90. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 91. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 92. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 93. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 94. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 95. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 96. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 97. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 98. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 99. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 100. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 101. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 102. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 103. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 104. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 105. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 106. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 107. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 108. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 109. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 110. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 111. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 112. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 113. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 114. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 115. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 116. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 117. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 118. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 119. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 120. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 121. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 122. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 123. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 124. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 125. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 126. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 127. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Country

Table 128. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 129. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 130. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 131. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 132. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 133. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 134. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 135. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 136. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 137. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 138. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 139. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 140. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 141. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 142. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 143. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 144. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 145. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 146. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 147. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 148. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 149. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 150. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 151. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 152. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 153. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 154. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 155. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 156. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 157. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 158. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Country

Table 159. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 160. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 161. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 162. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 163. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 164. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 165. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 166. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 167. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 168. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 169. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 170. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 171. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Offering

Table 172. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Deployment

Table 173. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Enterprise Size

Table 174. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Form

Table 175. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by Functionality

Table 176. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million) – by End User

Table 177. Company Positioning & Concentration

Table 178. List of Abbreviation

List of Figures

Figure 1. Pharmacovigilance and Drug Safety Software Market Segmentation, by Geography

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Pharmacovigilance and Drug Safety Software Market Revenue (US$ Million), 2021–2031

Figure 5. Pharmacovigilance and Drug Safety Software Market Share (%) – by Offering (2023 and 2031)

Figure 6. Software: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 7. Services: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 8. Pharmacovigilance and Drug Safety Software Market Share (%) – by Deployment (2023 and 2031)

Figure 9. Cloud: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 10. On Premises: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 11. Pharmacovigilance and Drug Safety Software Market Share (%) – by Enterprise Size (2023 and 2031)

Figure 12. Large Enterprises: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 13. SMEs: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 14. Pharmacovigilance and Drug Safety Software Market Share (%) – by Form (2023 and 2031)

Figure 15. Standard: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 16. Customized: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 17. Pharmacovigilance and Drug Safety Software Market Share (%) – by Functionality (2023 and 2031)

Figure 18. Signal and Risk Management: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 19. Issue Tracking and Adverse Event Tracking: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 20. Case Management: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 21. Clinical Safety Management and Clinical Trial Safety: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 22. Quality and Compliance: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 23. Medical Writing: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 24. Audit Support and Training Compliance: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 25. Healthcare Analytics: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 26. Others: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 27. Pharmacovigilance and Drug Safety Software Market Share (%) – by End User (2023 and 2031)

Figure 28. Pharmaceutical and Biotechnology Companies: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 29. Contract Research Organizations: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 30. Business Process Outsourcing (BPO) Firms: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 31. Others: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031 (US$ Million)

Figure 32. Pharmacovigilance and Drug Safety Software Market Breakdown by Region, 2023 and 2031 (%)

Figure 33. North America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 34. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering (2023 and 2031)

Figure 35. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment (2023 and 2031)

Figure 36. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size (2023 and 2031)

Figure 37. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form (2023 and 2031)

Figure 38. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality (2023 and 2031)

Figure 39. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User (2023 and 2031)

Figure 40. North America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 41. United States: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 42. Canada: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 43. Mexico: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 44. Europe: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 45. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering (2023 and 2031)

Figure 46. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment (2023 and 2031)

Figure 47. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size (2023 and 2031)

Figure 48. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form (2023 and 2031)

Figure 49. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality (2023 and 2031)

Figure 50. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User (2023 and 2031)

Figure 51. Europe: Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 52. Germany: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 53. France: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 54. United Kingdom: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 55. Italy: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 56. Spain: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 57. Russia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 58. Asia Pacific: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 59. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering (2023 and 2031)

Figure 60. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment (2023 and 2031)

Figure 61. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size (2023 and 2031)

Figure 62. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form (2023 and 2031)

Figure 63. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality (2023 and 2031)

Figure 64. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User (2023 and 2031)

Figure 65. Asia Pacific: Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 66. China: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 67. Japan: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 68. India: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 69. South Korea: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 70. Australia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 71. Rest of APAC: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 72. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 73. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering (2023 and 2031)

Figure 74. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment (2023 and 2031)

Figure 75. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size (2023 and 2031)

Figure 76. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form (2023 and 2031)

Figure 77. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality (2023 and 2031)

Figure 78. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User (2023 and 2031)

Figure 79. Middle East and Africa: Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 80. Saudi Arabia: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 81. United Arab Emirates: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 82. South Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 83. Rest of Middle East and Africa: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 84. South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 85. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Offering (2023 and 2031)

Figure 86. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Deployment (2023 and 2031)

Figure 87. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Enterprise Size (2023 and 2031)

Figure 88. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Form (2023 and 2031)

Figure 89. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Functionality (2023 and 2031)

Figure 90. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by End User (2023 and 2031)

Figure 91. South and Central America: Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 92. Brazil: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 93. Argentina: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 94. Rest of South and Central America: Pharmacovigilance and Drug Safety Software Market – Revenue and Forecast to 2031(US$ Million)

Figure 95. Heat Map Analysis by Key Players

The List of Companies - Pharmacovigilance and Drug Safety Software Market

  1. ArisGlobal LLC     
  2. Max Application    
  3. Oracle Corp         
  4. Veeva Systems Inc           
  5. IQVIA Holdings Inc           
  6. ICON Plc             
  7. Cognizant Technology Solutions Corp       
  8. Accenture Plc      
  9. Syneos Health Inc
  10. Genpact Ltd.     

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmacovigilance and Drug Safety Software Market